In
Implementation of medical and health research by Astellas:
Astellas is conducting a medical and health research using the application co-developed by the two companies for medical and health research in accodance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects. This medical and health research will evaluate the effect of an excercise program that combines aerobic and resistance exercises (repetitive exercises that exert resistance on target muscles) provided by the application on an individual's body by assessing indicators such as changes in visceral fat area.
Co-development of application for pilot marketing: The two companies will co-develop the application for planned pilot marketing. The objective of the co-development is to build upon the application used for the above medical and health research by improving 'user experience' and 'user interface' to seek continuity and habituation of exercises so that users will personally take interest and start using the application and continue the exercises. This will be accomplished through leveraging game development know-how by combining fun and exercise.
About Astellas
About
Astellas Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.
Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
Contact:
Tel: +81-3-3244-3201
(C) 2020 Electronic News Publishing, source